Inhibition of angiogenesis in lipodermatosclerosis: Implication for venous ulcer formation

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 645-651

  Herouy, Yared ^a,b   Kreis, Sebastian ^b   Mueller, Tobias ^b   Duerk, Thorstein ^b   Martiny Baron, Georg ^c   Reusch, Petra ^d   May, Florian ^e   Idzko, Marco ^b   Norgauer, Johannes ^f  

^a Outpatient Department and Private Practice   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TUMOR BIOLOGY CENTER   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Angiogenesis; Angiopoietin; Lipodermatosclerosis; Vascular endothelial growth factor; VEGF receptor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BETA 2 MICROGLOBULIN; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPODERMATOSCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; ULCEROGENESIS; UPREGULATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; SCLEROSIS; VARICOSE ULCER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70350768852     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000275     Document Type: Article

References (29)

1. Kirsner RS, Pardes JB, Eaglstein WH and Falanga V: The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol 28: 623-627, 1993.
2. Ciulla TA and Rosenfeld PJ: Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20: 158-165, 2009.
3. Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe PE, Brekken RA, Gatter KC, Harris AL, Koukourakis IM and Koukourakis MI: The angiogenic pathway 'vascular endothelial growth factor/ flk-1(KDR)-receptor' in rheumatoid arthritis and osteoarthritis. J Pathol 194: 101-108, 2001.
4. Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM, Mostoslavsky G, Smith LE and Ingber DE: A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature 457: 1103-1108, 2009.
5. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T and Shibuya M: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61: 1207-1213, 2001.
6. Barcelos LS, Duplaa C, Kränkel N, Graiani G, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M, Simm A, Campagnolo P, Mangialardi G, Stevanato L, Alessandri G, Emanueli C and Madeddu P: Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 104: 1095-1102, 2009.
7. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
8. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
9. Larrivee B and Karsan A: Signaling pathways induced in vascular endothelial growth factor. Int J Mol Med 5: 447-456, 2000.
10. Bautch VL, Redick SD, Scalia A, Harmaty M, Carmeliet P and Rapoport R: Characterization of the vasculogenic block in the absence of vascular endothelial growth factor-A. Blood 95: 1979-1987, 2000.
11. Lohela M, Bry M, Tammela T and Alitalo K: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165, 2009.
12. Dvorak HF: VPF/VEGF and the angiogenic respone. Semin Perinatol 24: 75-78, 2000.
13. Lobov IB, Brooks PC and Lang RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99: 110205-110210, 2002.
14. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
15. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN and Yancopoulos GD: Increased vascularization in mice overexpressing angiopoietin-1. Science 282: 468-471, 1998.
16. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
17. Holash J, Wiegand SJ and Yancopoulos GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18: 5356-5362, 1999.
18. Drinkwater SL, Burnand KG, Ding R and Smith A: Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg 38: 1106-1112, 2003.
19. Peschen M, Grenz H, Brand-Saberi B, Bunaes M, Simon JC, Schopf E, et al: Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency. Arch Dermatol Res 290: 291-297, 1998.
20. Drinkwater SL, Smith A, Sawyer BM and Burnand KG: Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg 89: 709-713, 2002.
21. Lauer G, Sollberg S, Cole M, Flamme I, Stürzebecher J, Mann K, Krieg T and Eming SA: Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 115: 12-18, 2000.
22. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marmé D and Augustin HG: Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 1721-1727, 2003.
23. Herouy Y, Trefzer D, Hellstern MO, Stark GB, Vanscheidt W, Schöpf E and Norgauer J: Plasminogen activation in venous leg ulcers. Br J Dermatol 143: 930-936, 2000.
24. Herrick SE, Sloan P, McGurk M, Freak L, McCollum CN and Ferguson MWJ: Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 141: 1085-1095, 1992.
25. Browse NL and Burnand KG: The cause of venous ulceration. Lancet 2: 243-245, 1982.
26. Coleridge Smith PD, Thomas P, Acurr JH and Dormandy JA: Causes of venous ulceration: A new hypothesis. Br Med J 296: 1726-1727, 1988.
27. Norgauer J, Hildenbrand T, Idzko M, Panther E, Bandemir E, Hartmann M, Vanscheidt W and Herouy Y: Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 147: 1180-1186, 2002.
28. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E and Olsen BR: Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14: 1236-1246, 2008.
29. Ballabh P, Xu H, Hu F, Braun A, Smith K, Rivera A, Lou N, Ungvari Z, Goldman SA, Csiszar A and Nedergaard M: Angiogenic inhibition reduces germinal matrix hemorrhage. Nat Med 13: 477-485, 2007.